Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases

• US 6,736,972 B1
• Filed: 03/23/2001
• Issued: 05/18/2004
• Est. Priority Date: 03/24/2000
• Status: Expired due to Term

• Current Assignee: Immunocept Medical Products, LLC (LMF Acquisition Opportunities, Inc.)
• Original Assignee: Immunocept LLC
• Inventors: Matson, James R.
• Primary Examiner(s): KIM, SUN U
• Application Number:
  US09/815,675
• Time in Patent Office: 1,152 Days
• Field of Search: 210/321, 210/6, 210/321.72, 210/645, 210/646, 210/650, 210/651, 422/44, 514/1, 514/2, 514/12, 514/21, 530/380, 530/381, 530/382, 530/383, 530/384, 424/85.2, 435/2, 435/219, 435/226, 604/4.01, 604/5.01, 604/5.02, 604/5.04, 604/6.09
• US Class Current: 210/650
• CPC Class Codes: A61M 1/342 Adding solutions to the blood, e.g. substitution solutions for preventing coagulation A61M1/3672
• CPC Class Codes: A61M 1/3437 downstream of the filter, e.g. post-dilution with filtrate
• CPC Class Codes: A61M 1/3441 Substitution rate control as a function of the ultrafiltration rate
• CPC Class Codes: A61M 1/3455 Substitution fluids
• CPC Class Codes: A61M 1/3458 having electrolytes not present in the dialysate
• CPC Class Codes: A61M 1/3468 using treated filtrate as substitution fluid
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents

Abstract

The present invention relates to a method and system for providing hemofiltration for reducing inflammatory mediator related diseases. In one form, a hemofiltration system for treating inflammatory mediator related diseases is disclosed. The system includes a hemofilter to receive blood from a specimen, the hemofilter removing selective inflammatory mediators from the blood and at least one therapeutic agent used in association with the hemofilter, the therapeutic agent to reduce adverse inflammatory mediator effects.

Claims

1. A hemofiltration system for treating inflammatory mediator related diseases, the system comprising:

a hemofilter operable to receive blood from a specimen and to selectively remove inflammatory mediators from the blood;

at least one therapeutic agent selected from the group consisting of allopurinol, elastase inhibitors and prostaglandin inhibitors;

the at least one therapeutic agent used in association with the hemofilter to treat an inflammatory mediator disease selected from the group consisting of systemic inflammatory response syndrome, multiorgan system dysfunction syndrome, multiorgan system failure and compensatory anti-inflammatory response syndrome; and

the therapeutic agent operable to reduce adverse inflammatory mediator effects.

2. The system of claim 1, wherein the hemofilter comprises a 100 to 150 kiloDalton hemofilter.

3. A method for treating inflammatory mediator related diseases, the method comprising:

receiving blood from a specimen;

filtering the blood using a hemofilter, to remove selective inflammatory mediators from the blood;

providing at least one therapeutic agent to the blood to reduce adverse inflammatory mediator effects associated with treating an inflammatory mediator disease selected from the group consisting of systemic inflammatory response syndrome, multiorgan system dysfunction syndrome, multiorgan system failure and compensatory anti-inflammatory response syndrome; and

the therapeutic agent comprises a pharmaceutical agent selected from the group consisting of allopurinol, elastase inhibitors and prostaglandin inhibitors.

4. A hemofiltration system for treating inflammatory mediator related diseases, the system comprising:

a hemofilter operable to receive blood from a specimen and to selectively remove inflammatory mediators from the blood;

the hemofilter comprising a 100 to 150 kiloDalton hemofilter;

the hemofilter associated with an adsorptive device;

at least one therapeutic agent used in association with the hemofilter to treat an inflammatory mediator disease selected from the group consisting of systemic inflammatory response syndrome, multiorgan system dysfunction syndrome, multiorgan system failure and compensatory anti-inflammatory response syndrome;

the therapeutic agent operable to reduce adverse inflammatory mediator effects; and

the therapeutic agent-selected from the group consisting of allopurinol, elastase inhibitors and prostaglandin inhibitors.

5. A method for treating inflammatory mediator related diseases, the method comprising:

receiving blood from a specimen;

filtering the blood using a bemofilter to remove selective inflammatory mediators from the blood; and

providing at least one therapeutic agent, selected from the group consisting of allopurinol, elastase inhibitors and prostaglandin inhibitors, to the blood to reduce adverse inflammatory mediator effects associated with treating an inflammatory mediator disease selected from the group consisting of systemic inflammatory response syndrome, multiorgan system dysfinction syndrome, multiorgan system failure and compensatory anti-inflammatory response syndrome.